{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:19:24Z","timestamp":1767849564154,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"KCDC, Korea"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.intimp.2011.03.020","type":"journal-article","created":{"date-parts":[[2011,4,22]],"date-time":"2011-04-22T00:45:56Z","timestamp":1303433156000},"page":"1195-1204","source":"Crossref","is-referenced-by-count":15,"title":["A combination of the TLR4 agonist CIA05 and alum promotes the immune responses to Bacillus anthracis protective antigen in mice"],"prefix":"10.1016","volume":"11","author":[{"given":"Seo Ri","family":"Wui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Kyeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeon Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hoon","family":"Chun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Je","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na Gyong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2011.03.020_bb0005","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1146\/annurev.micro.55.1.647","article-title":"Anthrax","volume":"55","author":"Mock","year":"2001","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0010","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1469-0691.2002.00500.x","article-title":"Anthrax in Europe: its epidemiology, clinical characteristics, and role in bioterrorism","volume":"8","author":"Schmid","year":"2002","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.intimp.2011.03.020_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0020","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1097\/00001432-200004000-00004","article-title":"Current status of immunization against anthrax: old vaccines may be here to stay for a while","volume":"13","author":"Turnbull","year":"2000","journal-title":"Curr Opin Infect Dis"},{"issue":"Suppl 4","key":"10.1016\/j.intimp.2011.03.020_bb0025","doi-asserted-by":"crossref","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"5","author":"Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0030","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.282.22.2104","article-title":"Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax","volume":"282","author":"Friedlander","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2011.03.020_bb0035","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/pds.936","article-title":"Safety of anthrax vaccine: an expanded review and evaluation of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS)","volume":"13","author":"Sever","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.intimp.2011.03.020_bb0040","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0264-410X(01)00387-5","article-title":"Anthrax vaccine: short-term safety experience in humans","volume":"20","author":"Pittman","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0045","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0050","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nm0204-112b","article-title":"US soldiers refuse to fall in line with anthrax vaccination scheme","volume":"10","author":"Ready","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.intimp.2011.03.020_bb0055","doi-asserted-by":"crossref","first-page":"10925","DOI":"10.1073\/pnas.1834478100","article-title":"A dually active anthrax vaccine that confers protection against both bacilli and toxins","volume":"100","author":"Rhie","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.intimp.2011.03.020_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-9433-4-4","article-title":"Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin","volume":"4","author":"Wang","year":"2005","journal-title":"Med Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0065","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/IAI.73.2.828-833.2005","article-title":"CpG oligodeoxynucleotides adsorbed onto polylactide\u2013co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine","volume":"73","author":"Xie","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.03.020_bb0070","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.vaccine.2006.07.056","article-title":"Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109","volume":"25","author":"Gu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0075","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1128\/IAI.01722-07","article-title":"Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant","volume":"76","author":"Park","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.03.020_bb0080","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1016\/j.vaccine.2006.04.048","article-title":"A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy","volume":"24","author":"Cho","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0085","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1574-695X.2007.00325.x","article-title":"Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen","volume":"51","author":"Song","year":"2007","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0090","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.intimp.2009.10.012","article-title":"A nontoxic derivative of lipopolysaccharide increases immune responses to Gardasil HPV vaccine in mice","volume":"10","author":"Han","year":"2010","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0095","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s12272-001-2121-2","article-title":"Enhancement of the immune responses of mice to Bacillus anthracis protective antigen by CIA07 combined with alum","volume":"31","author":"Kim","year":"2008","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.intimp.2011.03.020_bb0100","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.femsim.2005.05.008","article-title":"Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis","volume":"45","author":"Rhie","year":"2005","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/abio.1998.2961","article-title":"Quantification of bacterial lipopolysaccharides by the purpald assay: measuring formaldehyde generated from 2-keto-3-deoxyoctonate and heptose at the inner core by periodate oxidation","volume":"267","author":"Lee","year":"1999","journal-title":"Anal Biochem"},{"key":"10.1016\/j.intimp.2011.03.020_bb0110","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0115","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","article-title":"Aluminium compounds for use in vaccines","volume":"82","author":"Lindblad","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0120","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0125","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.micinf.2007.08.002","article-title":"Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax","volume":"9","author":"Klinman","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.intimp.2011.03.020_bb0130","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0135","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1016\/j.vaccine.2006.06.005","article-title":"Enhanced humoral and memory B cellular immunity using HPV16\/18L1 VLP vaccine formulated with the MPL\/aluminium salt combination (AS04) compared to aluminium salt only","volume":"24","author":"Giannini","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0140","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.ki.5002725","article-title":"A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients","volume":"73","author":"Kong","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.intimp.2011.03.020_bb0145","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1348-0421.2007.tb04005.x","article-title":"Immune responses of mice to influenza subunit vaccine in combination with CIA07 as an adjuvant","volume":"51","author":"Park","year":"2007","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0150","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1128\/IAI.74.1.794-797.2006","article-title":"Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen","volume":"74","author":"Peachman","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.intimp.2011.03.020_bb0155","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1016\/j.vaccine.2008.05.068","article-title":"An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals","volume":"26","author":"Hewetson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.intimp.2011.03.020_bb0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev.iy.12.040194.001001","article-title":"Germinal centers","volume":"12","author":"MacLennan","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0165","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.coi.2005.04.007","article-title":"The primary germinal center response in mice","volume":"17","author":"Cozine","year":"2005","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0170","doi-asserted-by":"crossref","first-page":"5252","DOI":"10.4049\/jimmunol.150.12.5252","article-title":"Characterization of a novel cell-surface molecule expressed on subpopulations of activated T and B cells","volume":"150","author":"Laszlo","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0165-2478(01)00239-5","article-title":"Differential expression of GL7 activation antigen on bone marrow B cell subpopulations and peripheral B cells","volume":"78","author":"Cervenak","year":"2001","journal-title":"Immunol Lett"},{"key":"10.1016\/j.intimp.2011.03.020_bb0180","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/1521-4141(200201)32:1<291::AID-IMMU291>3.0.CO;2-L","article-title":"GL7 defines the cycling stage of pre-B cells in murine bone marrow","volume":"32","author":"Murasawa","year":"2002","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.intimp.2011.03.020_bb0185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0092-8674(89)90761-7","article-title":"Primary antibody-forming cells and secondary B cells are generated from separate precursor cell subpopulations","volume":"59","author":"Linton","year":"1989","journal-title":"Cell"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576911001597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576911001597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T12:22:00Z","timestamp":1686054120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576911001597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1567576911001597"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2011.03.020","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}